Open AccessAlectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin
Author(s) -
Nakai Ritsuko,
Fukuhara Suguru,
Maeshima Akiko Miyagi,
Kim SungWon,
Ito Yuta,
Hatta Shunsuke,
Suzuki Tomotaka,
Yuda Sayako,
Makita Shinichi,
Munakata Wataru,
Suzuki Tatsuya,
Maruyama Dai,
Izutsu Koji
Publication year - 2019
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.2543
Subject(s) - alectinib , medicine , brentuximab vedotin , anaplastic large cell lymphoma , anaplastic lymphoma kinase , refractory (planetary science) , chemotherapy , lymphoma , oncology , transplantation , autologous stem cell transplantation , cancer research , cd30 , physics , astrobiology , malignant pleural effusion , lung cancer
This is the first case report of alectinib as a bridge to allo‐SCT in a patient with ALK‐positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis.